Transgene (EU: TNG)

Last close As at 20/06/2024

2.49

0.00 (0.00%)

Market capitalisation

209m

Edison Investment Research is terminating coverage on Transgene. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Latest Insights

View More

Healthcare | Update

Transgene — TG4001 first efficacy data presented at ESMO

Healthcare | Outlook

Transgene — PHOCUS turns to earlier-stage assets

Healthcare | Update

Transgene — Defining data from lead assets by year-end

Healthcare | Update

Transgene — TG4010 and Pexa-Vec readouts to define 2019

Financials

Edison Investment Research is terminating coverage on Transgene. Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant.

Previously published reports can still be accessed via our website.

Research

Outlook

Healthcare

Transgene — Near-term data to define long-term strategy

Update

Healthcare

Transgene — 2018: A year of clinical data

Update

Healthcare

Transgene — Combination trials start, FY16 results

Update

Healthcare

Transgene — Update 28 October 2016

Update

Healthcare

Transgene — Update 21 September 2016

Outlook

Healthcare

Transgene — Update 13 April 2016

Thematics

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

thematic

Healthcare

ASCO 2023 key takeaways

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free